News | May 12, 2010

ICD Monitors ST-Segment For Early Cardiac Event Detection

May 12, 2010 – The Japanese Ministry of Health, Labor and Welfare (MHLW) today cleared the AnalyST implantable cardioverter defibrillator (ICD) with ST-monitoring in Japan. The device continuously monitors ST segments as an early warning system for cardiac problems.

The AnalyST ICD with ST monitoring is the industry’s first device to continuously monitor specific changes in the heart’s electrical system that can indicate conditions such as ischemia. Learning about these conditions earlier may lead to more timely diagnosis and therapy for patients, and possibly improve patient prognosis.

Because many cardiac episodes are transient in nature, continuous ST monitoring gives physicians more comprehensive ST segment information over time, rather than a sporadic, hit-or-miss diagnostic report. In the near future, physicians also will be able to monitor patients’ ST segment changes via remote transmissions from the St. Jude Medical [email protected] transmitter. The wireless remote monitoring system in allows for device information transmission from a patient’s home to their physician’s office.

“The AnalyST ICD is the only implantable device that provides ST segment monitoring reports via high-quality, intracardiac electrograms, as well as additional ST segment diagnostic reports,” said Morio Shoda, M.D., associate professor, department of cardiology at the Tokyo Women’s Medical University. “I look forward to accessing this new and valuable information for more insight into the condition of my ICD patients with ischemia or idiopathic VF, including Brugada syndrome.”

The surface electrocardiogram (ECG) has been the gold standard for diagnosing risk for heart tissue damage and arrhythmias. However, surface ECG has limitations: it provides only a few seconds of information at a time, it cannot be used to continuously monitor the patient over a long period, and it is susceptible to poor signal quality. The AnalyST ICD provides continuous information and high-fidelity electrograms from the inside of the heart.

The AnalyST ICD also includes:

• DeFT Response, which is designed to help devices meet the needs of patients who may have high or varying thresholds for the amount of energy required to defibrillate the heart. This enables the physician to tailor device therapy for individual patients, offering them added protection in the event of a life-threatening arrhythmia.

• The VIP (Ventricular Intrinsic Preference) algorithm provides a delay in device stimulation of the lower chambers of the heart to allow the patient's own heart rhythm to prevail when possible. The VIP technology is designed to provide device stimulation only when needed.

• SenseAbility technology is designed to optimize sensing to help protect against inappropriate shocks.

•Vibrating patient notifier gently vibrates to warn patients if the device is not performing as designed.

The AnalyST ICD is not approved for use in the United States.

For more information:

Related Content

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

A physician explaining an implantable cardioverter defibrillator (ICD) to a patient. Image courtesy of Biotronik.

Feature | Implantable Cardioverter Defibrillator (ICD) | May 24, 2019 | Dave Fornell, Editor
This is a brief overview of updates on...
Emblem Subcutaneous ICD Safe and Effective for Majority of Patients
News | Implantable Cardioverter Defibrillator (ICD) | May 13, 2019
May 13, 2019 — Boston Scientific announced acute results from the UNTOUCHED study evaluating safety and efficacy of t
Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Overlay Init